Key points are not available for this paper at this time.
What is this summary about? This is a summary of a paper published in The Lancet medical journal describing the results of the NefIgArd clinical trial, which looked at Nefecon treatment in people with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by a special type of antibody called galactosedeficient immunoglobulin A (gd-IgA), which collects in the kidneys. This triggers inflammation (which is the body fighting disease) and damages the kidneys over time (nephropathy), often leading to kidney failure. Nefecon is a new pill containing a medicine called budesonide and acts in the lower part of the small intestine, where the IgAN disease process is thought to start.
Lafayette et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: